Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of PF-07220060 plus fulvestrant versus investigator's choice in HR-positive, HER2-negative advanced breast cancer after prior CDK4/6 inhibitor therapy
MOH_2024-01-29_013218Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atirmociclib and fulvestrant in breast cancer (3 arms), sponsored by Pfizer. Started Jan 2024; status: recruiting.
02
Drugs
atirmociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-01-29_013218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-29_013218.